Palo Alto, CA – April 24, 2026 – LVIS Corporation, a neurotechnology company focused on AI-powered clinical diagnostics, has been recognized as a Silver Winner at the 2026 Edison Awards for its work advancing neurological disease detection through artificial intelligence.
The Edison Awards, widely recognized for honoring innovation across industries, celebrate organizations developing products and technologies that address real-world challenges through measurable impact. LVIS Corporation’s recognition highlights its continued efforts to improve neurological diagnostics through AI systems designed to support physicians in identifying and interpreting complex brain network activity.
As healthcare systems continue to face increasing demand for neurological care, healthcare providers are seeking technologies that improve diagnostic efficiency while preserving physician oversight. AI-supported clinical tools have become an area of growing focus across healthcare, particularly in specialties where access to timely expertise remains limited.
LVIS Corporation’s recognition reflects a broader industry shift toward clinically integrated AI solutions that support providers in delivering faster, data-driven insights. The company’s NeuroMatch platform uses advanced neural information analysis technology to decode brain networks and generate visualizations that support neurological disease diagnosis.
“Recognition from the Edison Awards highlights the importance of developing AI technologies that work alongside physicians to improve diagnostic confidence and expand access to neurological care,” said Dr. Jin Hyung Lee, Founder of LVIS Corporation.
The Silver Award distinction places LVIS Corporation among a group of organizations recognized for innovation across healthcare, technology, engineering, and consumer industries. The award program evaluates submissions based on concept, value, delivery, and impact.
LVIS Corporation continues to work alongside healthcare providers, hospital systems, and clinical partners to advance AI-supported neurological diagnostics that align with evolving clinical needs and patient care standards.